Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Capital One Financial Corporation

Announced: February 19, 2024
Value: $35.3 billion
Status: Pending

Exclusive financial advisor to Capital One on its acquisition of Discover

Endeavor Group Holdings, Inc.

Announced: April 2, 2024
Value: $25 billion
Status: Pending

Exclusive financial advisor to the Special Committee of Endeavor on its sale to Silver Lake

ChampionX Corporation

Announced: April 2, 2024
Value: $8.2 billion
Status: Pending

Exclusive financial advisor to ChampionX on its sale to SLB

Alpine Immune Sciences, Inc.

Announced: April 10, 2024
Value: $4.95 billion
Status: Pending

Exclusive financial advisor to Alpine on its sale to Vertex

CymaBay Therapeutics, Inc.

Announced: February 12, 2024
Value: $4.3 billion
Status: Pending

Lead financial advisor to CymaBay on its sale to Gilead

The Cigna Group

Announced: January 31, 2024
Value: $3.7 billion
Status: Pending

Lead financial advisor to Cigna on the sale of its Medicare Businesses and CareAllies to HCSC

MorphoSys AG

Announced: February 5, 2024
Value: €2.7 billion
Status: Pending

Exclusive financial advisor to MorphoSys on its sale to Novartis

Agiliti Inc.

Announced: February 26, 2024
Value: $2.5 billion
Status: Pending

Exclusive financial advisor to the Special Committee of Agiliti on its sale to THL Partners

Fusion Pharmaceuticals Inc.

Announced: March 19, 2024
Value: Up to $2.4 billion
Status: Pending

Exclusive financial advisor to Fusion on its sale to AstraZeneca

Inhibrx

Announced: January 22, 2024
Value: Up to $2.2 billion
Status: Pending

Exclusive financial advisor to Inhibrx on its sale to Sanofi and pro rata distribution of shares in a new publicly traded biopharma company

Ambrx, Inc.

Announced: January 8, 2024
Value: $2 billion
Status: Pending

Lead financial advisor to Ambrx on its sale to Johnson & Johnson

HireRight Holdings Corporation

Announced: February 16, 2024
Value: $1.65 billion
Status: Pending

Exclusive financial advisor to the Special Committee of HireRight on its sale to General Atlantic and Stone Point

Cardior Pharmaceuticals GmbH

Announced: March 25, 2024
Value: Up to €1.025 billion
Status: Pending

Exclusive financial advisor to Cardior on its sale to Novo Nordisk

Amolyt Pharma SAS

Announced: March 14, 2024
Value: Up to $1.05 billion
Status: Pending

Lead financial advisor to Amolyt Pharma on its sale to AstraZeneca

Harpoon Therapeutics, Inc.

Announced: January 8, 2024
Value: $680 million
Status: Pending

Exclusive financial advisor to Harpoon on its sale to Merck

Kimberly-Clark Corporation

Announced: April 7, 2024
Value: $640 million
Status: Pending

Financial advisor to Kimberly-Clark on the sale of its Personal Protective Equipment business to Ansell

Accor SA

Announced: March 12, 2024
Value: €275 million
Status: Closed

Exclusive financial advisor to Accor on its share repurchase from Jinjiang International

The Children's Place, Inc

Announced: February 29, 2024
Value: $78.6 million
Status: Closed

Exclusive financing advisor to The Children's Place on its financing agreement with Mithaq Capital

Disney

Announced: April 3, 2024
Status: Closed

Advisor to Disney in connection with its proxy contest with Trian Partners and Blackwells, as well as its settlement with ValueAct

Advance Auto Parts Inc.

Announced: March 11, 2024

Exclusive financial advisor to Advance Auto Parts on the announcement of a cooperation agreement with Third Point and Saddle Point

Ventas Inc.

Announced: March 4, 2024
Status: Pending

Financial advisor to Ventas on the announcement of a cooperation agreement with Land & Buildings

Avison Young (Canada) Inc.

Announced: February 26, 2024
Status: Pending

Financial advisor to Avison Young on its recapitalization transaction and new capital investment

Delphix

Announced: February 14, 2024
Status: Pending

Exclusive financial advisor to Delphix on its sale to Perforce

REV Group, Inc.

Announced: February 13, 2024
Status: Pending

Exclusive financial advisor to the Special Committee of REV Group regarding its secondary offering and share repurchase of American Industrial Partners' ownership stake

Dave.com

Announced: January 30, 2024
Status: Closed

Exclusive financial advisor to Dave on its repurchase of a convertible note from FTX

Radiology Partners, Inc.

Announced: January 19, 2024
Status: Closed

Exclusive financial advisor to an ad-hoc group of crossover creditors on Radiology Partners' set of refinancing transactions

Diamond Sports Group, LLC

Announced: January 17, 2024
Status: Pending

Exclusive financial advisor to the ad-hoc group of first lien creditors on Diamond Sports Group's Restructuring Support Agreement and investment from Amazon

Wolverine World Wide, Inc.

Announced: January 11, 2024
Status: Closed

Exclusive financial advisor to Wolverine on the sale of Sperry to Authentic Brands and ALDO

Informa plc

Announced: January 10, 2024
Status: Pending

Financial advisor to Informa on the combination of Informa Tech's digital businesses with TechTarget

Wiley

Announced: January 9, 2024
Status: Pending

Financial advisor to Wiley on the divestiture of its Wiley Edge business to Inspirit Capital

Danone S.A.

Announced: January 2, 2024
Status: Pending

Exclusive financial advisor to Danone on the sale of a majority stake in its U.S. premium organic dairy business to Platinum Equity

Showing 1 to 31 of 31
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.